U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
RegulatoryapprovedInluriyoVerzenioPositive
AI Analysis
Summary
The FDA approved Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer, based on positive Phase 3 EMBER-3 trial data showing doubled median progression-free survival.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
FDA approval for Inluriyo in combination with Verzenio for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Importance:9/10
Sentiment:
0.95
FDA approvalbreast cancercombination therapyPhase 3
Read the original article
Published by PR Newswire Biotech on September 18, 2026 5:54 PM